Regulatory standard

Drug Shortages and Compounding Authority

Official shortage status; dates; stabilization; enforcement discretion; copies; changing rules.

What is established about official shortage status?

For drug shortage compounding rules, official shortage status is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.

Where official shortage status has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.

What is established about dates?

For drug shortage compounding rules, dates is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.

Where dates has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.

What is established about stabilization?

For drug shortage compounding rules, stabilization is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.

Where stabilization has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.

What is established about enforcement discretion?

For drug shortage compounding rules, enforcement discretion is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.

Where enforcement discretion has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.

What is established about copies?

For drug shortage compounding rules, copies is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.

Where copies has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.

What does this page establish?

It establishes the framework and the source map for drug shortage compounding rules, drawn from FDA primary sources verified on 2026-07-23. Framework facts — what the statute says, what registration means, which agency holds which record — are stable and checkable, and they are cited inline.

What it does not establish is any entity-specific fact. This platform separates those two categories deliberately, because they carry different verification burdens. A statutory definition can be cited once and relied on; a pharmacy's licence status changes continuously and must be checked at the moment of use.

Status terms on this page follow the platform's published status vocabulary.

Why drug shortage compounding rules is hard to verify

Three structural features of compounding oversight make verification harder than it looks, and they apply to this topic as much as any other.

First, authority is split. Federal and state regulators hold different records about the same entity, and neither register is complete on its own. Second, registration and inspection are separate events — a facility can be registered for years without an inspection, so a registration date tells you nothing about oversight intensity. Third, a record's currency is invisible without its date: a licence verified last year and a licence verified today look identical in a citation.

That is why every field on this platform carries a check date, and why a field without one renders as pending rather than as a fact.

Why does shortage listing change what is lawful?

Because the restriction on compounding a copy exists to protect the approval system, and that rationale weakens when the approved product cannot actually be obtained. A patient who cannot get the approved drug is not being diverted from it.

So the shortage list functions as a switch. On the list, compounders may prepare what would otherwise be an unlawful copy. Off it, they may not. The switch is binary and it is the agency's to flip, which is why the determination that a shortage is resolved is itself a legal event rather than an administrative note.

It also explains why the transition periods existed. FDA set staged deadlines rather than an immediate cut-off because compounders held stock, prescriptions were in flight, and patients were mid-treatment.

What happens to patients when the switch flips?

This is the part the regulatory record does not address, and it is the part that matters most to a reader. When enforcement discretion ended, patients on compounded preparations faced three options: transition to the approved product at substantially higher cost, stop, or find a supplier still operating.

The withdrawal evidence makes the second option consequential. Stopping produces substantial weight regain, so an interruption is not a neutral pause. And the third option carries the verification burden this platform exists to document.

The honest summary is that the regulatory change was correct on its own terms and created a real access problem at the same time. Both things are true, and coverage that reports only one is incomplete.

What this currently costs

Price is one of the few variables a reader can act on directly, so it is reported here rather than left to a separate page. Among the programmes this platform has verified by recomputation, the lowest regular injection rate is $145 per month on the longest commitment tier (NexLife), against higher rates on shorter terms.

Every tier behind that figure was recomputed from the published total rather than taken from the advertised per-month rate — 16 of 18 reconcile exactly, and the two that do not are published with the corrected figure on the regular injection affordability page.

The timeline that closed the compounded GLP-1 market

The compounded GLP-1 market rested on one legal fact: while a drug sits on the FDA shortage list, the bar against compounding an essentially-a-copy product lifts. Both shortages are over, and the exception closed with them. This is the exact sequence, each step traceable to an FDA order or a court decision.

Two consequences follow that are easy to miss. First, the 503A and 503B deadlines were different — 18 February and 19 March 2025 — so a pharmacy and an outsourcing facility were operating under different rules for a month. Second, the April 2026 bulks-list proposal would close the route permanently rather than temporarily: even a future shortage would not reopen it if the substances are formally excluded.

Related records in this section

Section hub: Regulatory standards · Methodology · Status definitions · Right to respond

Sources

• FDA — Information for Outsourcing Facilities
• FDA — Q&A: Outsourcing Facility Registration
• FDA — Registered Outsourcing Facilities
• FDA — Aligning Federal and State Regulation of Compounders
• FDA — Outsourcing Facility Fees
• FDA — Compounded Drug Products That Are Essentially Copies
• FDA — Proposes to Exclude Semaglutide, Tirzepatide and Liraglutide from 503B Bulks List (30 Apr 2026)
• FDA — Registration of Human Drug Compounding Outsourcing Facilities (guidance)
• Nevada Board of Pharmacy — Notice of FDA Declaratory Orders (tirzepatide, semaglutide)
• FDA — Outsourcing Facility Fees guidance

Update history

Dates change only for substantive updates. Entities may submit a correction or response through the right-to-respond process.